Key takeaways
Invokamet (canagliflozin / metformin) and saxagliptin are both medications used to treat Type 2 diabetes. However, they belong to different medication classes. Invokamet is a combination of a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a biguanide, while saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. Invokamet is available as immediate-release tablets taken twice daily or extended-release tablets taken once daily, whereas saxagliptin is taken once daily. Invokamet is only available as a brand-name medication, while saxagliptin is available in a generic form and used to be available as brand-name Onglyza. Invokamet can cause side effects like urinary tract infections, yeast infections, and frequent urination, while saxagliptin may lead to upper respiratory infections and headaches. Both medications can interact with other diabetes medications, potentially causing low blood sugar.
